Skip to main content
Healthcare

STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Feed excerpt — reported by STAT News

An experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.